Geographical comparison of cancer survival in European children (1988-1997): Report from the Automated Childhood Cancer Information System project.

Abstract The aim of this study was to assess regional survival differences among childhood cancer patients in Europe. For this exercise, the Automated Childhood Cancer Information System (ACCIS) database was utilised. Survival data from 54 population-based cancer registries on 49,651 childhood cancer patients aged 0-14 years and diagnosed in 1988-1997 were analysed using life-table method. Overall, the 5-year survival was 72% among all patients, varying from 62% to 77% between the five geographical regions. The East region generally had lower survival rates than the rest of Europe. The geographical differences indicate the need for more co-ordination, systematisation and standardisation in diagnosis, referral and the treatment of childhood cancers in Europe. Increase of resources is necessary to improve the lower survival in the East region. Continuing data collection on a European level will facilitate monitoring of population-based survival of childhood cancer patients

Impact of gastrointestinal physiology on drug absorption in special populations??An UNGAP review

The release and absorption profile of an oral medication is influenced by the physicochemical properties of the drug and its formulation, as well as by the anatomy and physiology of the gastrointestinal (GI) tract. During drug development the bioavailability of a new drug is typically assessed in early clinical studies in a healthy adult population. However, many disease conditions are associated with an alteration of the anatomy and/or physiology of the GI tract. The same holds true for some subpopulations, such as paediatric or elderly patients, or populations with different ethnicity. The variation in GI tract conditions compared to healthy adults can directly affect the kinetics of drug absorption, and thus, safety and efficacy of an oral medication. This review provides an overview of GI tract properties in special populations compared to healthy adults and discusses how drug absorption is affected by these conditions. Particular focus is directed towards non-disease dependent conditions (age, sex, ethnicity, genetic factors, obesity, pregnancy), GI diseases (ulcerative colitis and Crohn's disease, celiac disease, cancer in the GI tract, Roux-en-Y gastric bypass, lactose intolerance, Helicobacter pylori infection, and infectious diseases of the GI tract), as well as systemic diseases that change the GI tract conditions (cystic fibrosis, diabetes, Parkinson's disease, HIV enteropathy, and critical illness). The current knowledge about GI conditions in special populations and their impact on drug absorption is still limited. Further research is required to improve confidence in pharmacokinetic predictions and dosing recommendations in the targeted patient population, and thus to ensure safe and effective drug therapies.status: publishe

The Vulcan Petawatt interaction facility

The Vulvan Nd:glass laser at the Central Laser Facility (CLF) has recently been upgraded to the Petawatt level (1015 Watts). The three year upgrade project was contracted to deliver 500 J in a near diffraction limited pulse of 500 fs duration. The Petawatt facility will deliver an irradiance on target of 1021 W.cm-2 for a wide ranging experimental programme in fundamental physics and advanced applications. This includes the interaction of super-high intensity light with matter, fast ignition fusion research, photon induced nuclear reactions, electron and ion acceleration by light waves and the exploration of the exotic world of plasma physics dominated by relativity. Of particular relevance to high speed photography, the Petawatt beam will be used to create a source for advanced high-speed imaging using protons, neutrons and X-rays on an hitherto inaccessible time-scale